http://www.fpnotebook.com/
Topical Antibiotics
Aka: Topical Antibiotics, Bacitracin, Bactroban, Mupirocin- Preparations
- Bacitracin
- Mupirocin (Bactroban)
- Retapamulin (Altabax)
| Medication Costs | ||
|---|---|---|
| Bacitracin-Polymyxin B (on 2/9/2012 at DrugStore.com) | ||
| Bacitracin-Polymyxin B 500-10000unit/gm Ointment 3.5gm Tube | #1 for $31.99 | ($31.99/unit) |
| Bactroban (on 2/9/2012 at DrugStore.com) | ||
| Bactroban 2% Ointment 22gm Tube | #1 for $79.99 | ($79.99/unit) |
| Bactroban 2% Cream 15gm Tube | #1 for $64.99 | ($64.99/unit) |
| Bactroban 2% Cream 30gm Tube | #1 for $96.99 | ($96.99/unit) |
| Bactroban Nasal (on 2/9/2012 at DrugStore.com) | ||
| Bactroban Nasal 2% Ointment 1gm Tube | #1 for $19.99 | ($19.99/unit) |
| Mupirocin (on 2/9/2012 at DrugStore.com) | ||
| Mupirocin 2% Ointment 22gm Tube | #1 for $37.99 | ($37.99/unit) |
| FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. | ||
Bacitracin (C0004599) |
|
|---|---|
| Definition (MSH) | A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140) |
| Definition (NCI) | A complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall. The binding interferes with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth. |
| Concepts | Amino Acid, Peptide, or Protein (T116) , Antibiotic (T195) |
| MSH | D001414 |
| SnomedCT | 255965000, 5220000, 370330005 |
| English | Bacitracin, NOS, bacitracin, bacitracin (medication), BACITRACIN, Bacitracin [Chemical/Ingredient], bacitracins, Bacitracin (substance), Bacitracin product (product), Bacitracin product, BAC, Bacitracin, Bacitracin [dup] (substance) |
| Swedish | Bacitracin |
| Czech | bacitracin |
| Spanish | Bacitracin, Bacitracin [dup] (substance), bacitracina (producto), producto con bacitracina (producto), producto con bacitracina, bacitracina (sustancia), bacitracina, Bacitracina |
| Finnish | Basitrasiini |
| Russian | BATSITRATSIN, БАЦИТРАЦИН |
| Polish | Bacytracyna |
| Japanese | バシトラシン, アイフィビス |
| French | Bacitracine |
| German | Bacitracin |
| Italian | Bacitracina |
| Portuguese | Bacitracina |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Mupirocin (C0085259) |
|
|---|---|
| Definition (MSH) | A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. |
| Definition (NCI) | A natural crotonic acid derivative extracted from Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by specific reversible binding to bacterial isoleucyl tRNA synthase. With excellent activity against gram-positive staphylococci and streptococci, it is primarily used for treatment of primary and secondary skin disorders, nasal infections, and wound healing. (NCI04) |
| Concepts | Lipid (T119) , Antibiotic (T195) |
| MSH | D016712 |
| SnomedCT | 387397004, 71453003 |
| English | Acid, Pseudomonic, Mupirocin, Pseudomonic Acid, Pseudomonic Acid A, Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R*(1R*,2R*))))-, mupirocin, mupirocin (medication), MUPIROCIN, Mupirocin [Chemical/Ingredient], pseudomonic acid a, Pseudomonic acid, Pseudomonic acid A, Mupirocin (product), Mupirocin (substance) |
| Spanish | Ácido Pseudomónico, Acido Pseudomonico, mupirocina (producto), mupirocina (sustancia), mupirocina, ácido pseudomónico A, ácido pseudomónico, ácido seudomónico, Acido Seudomonico, Mupirocina, Ácido Seudomónico |
| Swedish | Mupirocin |
| Czech | mupirocin |
| Finnish | Mupirosiini |
| Russian | MUPIROTSIN, PSEVDOMONOVAIA KISLOTA, МУПИРОЦИН, ПСЕВДОМОНОВАЯ КИСЛОТА |
| Italian | Acido pseudomonico, Acido pseudomonico A, Mupirocina |
| Polish | Mupirocyna, Kwas pseudomonowy |
| Japanese | プソイドモニックアシド, ムピロシン |
| French | Acide pseudomonique, Mupirocine |
| German | Mupirocin, Pseudomonassäure |
| Portuguese | Ácido Pseudomônico, Mupirocina |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Bactroban (C0733863) |
|
|---|---|
| Concepts | Lipid (T119) , Antibiotic (T195) |
| MSH | D016712 |
| English | bactroban, Bactroban |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |